The Clinical Research Of Decompensated Hepatitis B Cirrhosis Treated With The Therapy Of Yiqihuoxue And Qinghualishui

Objective:To observe the clinical efficacy of Yiqihuoxue Qinghualishui treatment of decompensated Hepatitis B liver cirrhosis before and after treatment, including liver function, HBV-DNA, PT and ascites, portal vein diameter, symptoms and signs, compared with Western control group, discuss the superiority of Chinese medicine combined Western medicine treatment and evaluation to improve clinical symptoms and laboratory tests, delaying the progression of the disease, and other aspects of the effect of serum. Meanwhile to observe problems may be developed by its own side effects, and to evaluate the safety.Method:the choice of cases in line with Western medicine liver cirrhosis diagnosis and TCM bleeding resistance, wet internal resistance of the standard of the permit patients, from hospitalized patients of Jiangsu Provincial People’s Hospital, and Jiangsu Provincial Hospital of TCM, a total of60cases were divided into two groups,30cases in the treatment, group, and30cases in the control group. The control group with general symptomatic treatment, and the control group, with the TCM treatment of Yiqihuoxue Qinghualishui, and were treated to a course of treatment (6months) and observation of disease recorded before the treatment (0months), treatment of the medium term (three months), after treatment (6months) symptoms and signs Laboratory indicators of liver function, PT, HBV-DNA, liver fibrosis, alpha-fetoprotein, carcinoembryonic antigen, and the vein diameter, ascites, spleen size data and statistical data, analysis its efficacy differences.Results:(1) pre-treatment, two groups of patients have pre-albumin, albumin decreased, treatment has improved to some extent, different times of the non-parametric tests, all indicators were better than pre-treatment and significantly different (P<0.01); compared with the control group, the six month treatment group prealbumin increased significantly (P<0.01).(2) treatment group and control group in both groups serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBiL and), alkaline phosphatase (AKP), y-glutamyl glutamyl (y-GT), cholinesterase (CHE), serum albumin (ALB), prealbumin (pALB) non-parametric tests, all indicators better than those before treatment were significantly different (P<0.01); and in the6th month compared with control group, treatment group can significantly reduce AST, TBil,(P<0.01), significantly reduced ALT, y-GT (P<0.05).(3) three time points on the two sets of prothrombin time (PT), the Mauchly test of sphericity, all indicators have significant differences (P<0.01). To compared with the control group, the PT in the first6months of the treatment group improved significantly (P<0.05).(4) two sets of type Ⅲ procollagen, serum HA and collagen type IV after treatment decreased significantly, the three time points for non-parametric test, all groups than before treatment were significantly different (P<0.01). Two sets of phase, reduce serum HA III procollagen was no significant difference (P>0.05), but the treatment group than the control group in the first six months significantly reduced type IV collagen (P<0.05).(5) HBV-DNA of two groups after treatment were significantly decreased, the three time points for non-parametric tests, all the indicators over the previous significant difference (P<0.01). Lower HBV-DNA level treatment group in the first three months than the control group showed the advantage of a significant difference (P <0.05), but statistically significant in the reduction of HBV-DNA in the first6months two groups.(6) After treatment, the AFP than before, decreased significantly (P<0.05); two groups of CEA decreased significantly (P<0.01); groups after treatment compared with no significant difference (P>0.05). Two sets of doors after treatment (7) V trunk diameter, thickness of spleen and ascites depth than before treatment were decreased by the non-parametric tests, the index over the previous significant difference (P<0.01); compared with the control group, treatment The group can significantly reduce the the ascites depth (P<0.05), and significantly reduce the internal diameter of the main portal vein (P<0.01). No significant difference between the two groups to improve the spleen thickness (P>0.05).(8) in the treatment group after treatment than before treatment can significantly improve anorexia, fatigue symptoms (P<0.05), can significantly improve the hypochondriac pain, abdominal distension, ascites (P<0.01); control group, anorexia, abdominal distension improve without statistical significance (P>0.05), but can significantly improve the fatigue, hypochondriac pain, ascites situation (P<0.05). After treatment, compared to the treatment group was significantly different (P<0.05) in improving anorexia symptoms, a significant difference (P<0.01) in improving ascites, the rest of the symptoms was not statistically significant (P>0.05).Conclusion:Yiqihuoxue Qinghualishui combined with Western medicine treatment of decompensated Hepatitis B liver cirrhosis, than a simple conventional Western treatment, symptoms and signs, liver function, blood coagulation, HBV-DNA, liver fibrosis and some indicators of B-ultrasound, than the control group, and no significant adverse reactions and side effects during treatment with high security.